Replies to post #17181 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Any theories about what's driving today's price rise?

• MNTA is talking to multiple prospective partners re M923. (This is not really new info, but it hadn’t been mentioned in a while.)

• Possibility of 40mg-Glatopa approval before year-end is perhaps larger than investors thought after NVS took 40mg Glatopa out of 2017 guidance on its own 1Q17 CC.

• MNTA claims to have a commercialization path for M834 (Orencia) despite losing the recent IPR on BMY’s sub-Q-formulation patent.